RGNX Reports Q1 2026 Revenue $6.4M, $1.72 Loss per Share
REGENXBIO Inc. · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $7.14
-9.4% in 3d after detection
Post-detection moves
1h
—
1d
-8.4%
3d
-9.4%
7d
+1.0%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS